INVESTOR RELATIONS

News

Date Title and Summary Additional Formats
Toggle Summary NantKwest Appoints Dr. Leonard Sender as Senior Vice President of Medical Affairs for Pediatric, Adolescent and Young Adult Oncology
Company adds esteemed pediatric, adolescent and young adult oncology expert to leadership team CULVER CITY, Calif. --(BUSINESS WIRE)--May 16, 2017-- NantKwest Inc . (Nasdaq:NK), a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune
View HTML
Toggle Summary NantKwest to Present at 2017 Bank of America Merrill Lynch Healthcare Conference
CULVER CITY, Calif. --(BUSINESS WIRE)--May 15, 2017-- NantKwest (Nasdaq:NK), a leading, clinical-stage natural killer cell based therapeutics company, today announced that members of the company's management team will be presenting at the 2017 Bank of America Healthcare Conference on Thursday, May
View HTML
Toggle Summary NantKwest and NantCell Announce FDA Authorization for the NANT Cancer Vaccine Clinical Trials, the First Novel Combination of Innate and Adaptive Immunotherapy in Patients with Pancreatic Cancer
The NANT Cancer Vaccine, the First Simultaneous Combination of Off the Shelf Natural Killer Cells (NK) With Endogenous Adaptive Dendritic, T Cell and NK Cell Activation Personalized Molecular Informed Therapy with NantHealth's GPS Cancer as the Complementary Diagnostic for All Tumor Types A Cancer
View HTML
Toggle Summary NantKwest and Viracta Therapeutics Announce Series B Financing and Immunotherapy Partnership
by Jen Hodson | Apr 4, 2017 | Press Releases | Culver City and San Diego, CA   April 4, 2017 -  NantKwest, Inc. (Nasdaq:NK) and Viracta Therapeutics, Inc . announced the initial closing of a Series B Preferred financing round of up to $18.4 million with NantKwest, Inc .
View HTML
Toggle Summary NantKwest Announces FDA Grant of Orphan Drug Designation for the Company’s aNK Natural Killer Cell Therapy in Merkel Cell Carcinoma
CULVER CITY, Calif. --(BUSINESS WIRE)--Mar. 20, 2017-- NantKwest, Inc. (Nasdaq:NK), a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious diseases and inflammatory
View HTML
Toggle Summary NantKwest to Present at Upcoming Investor Conferences
CULVER CITY, Calif. --(BUSINESS WIRE)--Mar. 6, 2017-- NantKwest (Nasdaq:NK) today announced that members of the company’s management team will be presenting at the following upcoming investor conferences: Cowen & Company’s 37th Annual Healthcare Conference on Wednesday, March 8th , at 9:20am ET
View HTML
Toggle Summary Landmark First-In-Human Clinical Study Launch Using a Genetically Engineered Natural Killer Cell for the Treatment of Cancer
CULVER CITY, Calif. --(BUSINESS WIRE)--Jan. 23, 2017-- NantKwest Inc. (Nasdaq:NK), a pioneering, next-generation, clinical-stage immunotherapy company focused on harnessing the unique power of the immune system using natural killer (NK) cells to treat cancer, infectious diseases, and inflammatory
View HTML
Toggle Summary NantKwest to Host 2nd Annual Investor/Analyst Day Highlighting Industry Leading R&D and Clinical Programs
CULVER CITY, Calif. --(BUSINESS WIRE)--Dec. 19, 2016-- NantKwest (Nasdaq:NK), a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of the human immune system using natural killer (NK) cells to treat cancer, infectious diseases and inflammatory
View HTML
Toggle Summary NantKwest Announces Enhanced High-Affinity Activated Natural Killer (haNK) Cell Therapy in Preclinical Studies of HER2 Positive Breast Cancer at Presentation at the San Antonio Breast Cancer Symposium
CULVER CITY, Calif. --(BUSINESS WIRE)--Dec. 12, 2016-- NantKwest Inc. (Nasdaq:NK), a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious diseases and inflammatory
View HTML
Toggle Summary NantKwest to Present at the Piper Jaffray 28th Annual Health Care Conference
CULVER CITY, Calif. --(BUSINESS WIRE)--Nov. 28, 2016-- NantKwest Inc. (Nasdaq:NK) today announced that Company management will present at the Piper Jaffray 28 th Annual Health Care Conference in New York, NY at 4:00 pm Eastern Time (ET) on Tuesday, November 29, 2016 .
View HTML